TP53 and non-small cell lung carcinoma: This real-world retrospective cohort study included patients with advanced NSCLC and focused on the roles of both wild-type and mutant forms of p53 in the regulation of tumor development, such as tumor mutational burden (TMB), the level of programmed death receptor ligand 1 (PD-L1) protein on the surface of tumor tissue, their interplay with other genetic alterations and therapy response.